Inhibitory Effect of KWD 2131, Terbutaline, and DSCG on the Immediate and Late Allergen-Induced Bronchoconstriction

Abstract

.beta.-Adrenoceptor stimulants exhibit both bronchodilating and anti-allergic activities. KWD 2131 [1-(3,5-dihydroxyphenyl)-N-(1,1-dimethyl-2-hydroxyethyl)ethanolamine sulfate] is a new .beta.-agonist with preferably anti-allergic property. Nebulized KWD 2131 in a non-bronchodilating dose (0.25-0.50 mg) did not give significant protection against immediate reaction. Whether an increased nebulized dose of the new compound (5 mg) could protect against immediate and/or late response was evaluated. The response was compared with a nebulized dose of terbutaline (5 mg) and with twice the recommended dose DSCG [disodium cromoglycate] (40 mg). The study included 10 patients with known allergic asthma. It was designed as a single-blind cross-over trial with randomized allocation of the drugs. Lung functions were measured spirometrically and by body-plethysmograph; flow volume curves were drawn. KWD 2131 gave no significant protection against immediate reaction. Both terbutaline and DSCG did so, terbutaline being more efficient. Contrary to the .beta.-agonists, DSCG gave protection against late response.